Cost-effectiveness analysis of interventions to prevent cardiovascular disease in Vietnam

Health Policy and Planning

Volumn 26, Issue 3, 2011, Pages 210-222

  Ha, Duc Anh ^a,b   Chisholm, Dan ^c  

^a MINISTRY OF HEALTH   (Viet Nam)

^b BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

cardiovascular disease; cholesterol; Cost effectiveness; salt intake; systolic blood pressure; Vietnam

Indexed keywords

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; HEALTH SURVEY; HUMAN; MALE; MIDDLE AGED; PRIMARY PREVENTION; RISK REDUCTION; VIET NAM;

ADULT; AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; COST-BENEFIT ANALYSIS; FEMALE; HEALTH STATUS INDICATORS; HUMANS; MALE; MIDDLE AGED; PRIMARY PREVENTION; RISK REDUCTION BEHAVIOR; VIETNAM;

EID: 79251603018     PISSN: 02681080     EISSN: 14602237     Source Type: Journal    
DOI: 10.1093/heapol/czq045     Document Type: Article

References (63)

1. Adam T, Evans DB, Murray CJ. 2003. Econometric estimation of country-specific hospital costs. Cost Effectiveness and Resource Allocation 1: 3.
2. Antithrombotic Trialists Collaboration. 2002. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. British Medical Journal 324: 71-86.
3. Asaria P, Chisholm D, Mathers C et al. 2007. Chronic disease prevention: health effects and financial costs of strategies to reduce salt intake and control tobacco use. The Lancet 370: 2044-53. (Pubitemid 50007973)
4. Barrier PA, Li JTC, Jensen NM. 2003. Two words to improve physician-patient communication: what else? Mayo Clinic Proceedings 78: 211-6.
5. Betancourt JR, Carrillo JE, Green AR. 1999. Hypertension in multicul-tural and minority populations: linking communication to compli-ance. Current Hypertension Reports 1: 482-8.
6. Bovet P, Burnier M, Madeleine G et al. 2002. Monitoring one-year compliance to antihypertension medication in the Seychelles. Bulletin of the World Health Organization 80: 33-9. (Pubitemid 34151506)
7. Bradford RH, Shear CL, Chremos AN et al. 1991a. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Archives of Internal Medicine 151: 43-9.
8. Bradford RH, Shear CL, Chremos AN et al. 1991b. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: III. Efficacy in modifying lipoproteins and implications for managing patients with moderate hypercholesterolemia. American Journal of Medicine 91: 18S-24S.
9. Collins R, MacMahon S. 1994. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. British Medical Bulletin 50: 272-98. (Pubitemid 24165020)
10. Collins R, Peto R, MacMahon S et al. 1990. Blood pressure, stroke and coronary heart disease. Part 2: Short-term reductions in blood pressure: overview of randomised drug trials in their epidemio-logical context. The Lancet 335: 827-38. (Pubitemid 20113741)
11. Cuong TQ, Dibley MJ, Bowe S et al. 2007. Obesity in adults: an emerging problem in urban areas of Ho Chi Minh City, Vietnam. European Journal of Clinical Nutrition 61: 673-81. (Pubitemid 46722862)
12. Dahlof B, Sever PS, Poulter NR et al. 2005. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. The Lancet 366: 895-906. (Pubitemid 41265663)
13. Drummond MF. 2005. Methods for the Economic Evaluation of Health Care Programmes. Oxford: Oxford University Press.
14. Eastern Stroke and Coronary Heart Disease Collaborative Research Group. 1998. Blood pressure, cholesterol, and stroke in eastern Asia. The Lancet 352: 1801-7.
15. Edejer TTT, Baltussen R, Adam T et al. 2003. WHO Guide to Cost-Effectiveness Analysis. Geneva: World Health Organization.
16. Ekman B, Liem NT, Duc HA et al. 2008. Health insurance reform in Vietnam: a review of recent developments and future challenges. Health Policy and Planning 23: 252-63. (Pubitemid 351881994)
17. Ezzati M. 2004. Comparative Quantification of Health Risks: Global and Regional Burden of Disease Attributable to Selected Major Risk Factors. Geneva: World Health Organization.
18. Farquhar JW, Fortmann SP, Flora JA et al. 1990. Effects of community-wide education on cardiovascular disease risk factors. The Stanford Five-City Project. The Journal of the American Medical Association 264: 359-65. (Pubitemid 20219283)
19. Flessa S, Dung NT. 2004. Costing of services of Vietnamese hospitals: identifying costs in one central, two provincial and two district hospitals using a standard methodology. International Journal of Health Planning and Management 19: 63-77. (Pubitemid 38386688)
20. Forrester T, Adeyemo A, Soarres-Wynter S et al. 2004. A randomized trial on sodium reduction in two developing countries. Journal of Human Hypertension 19: 55-60.
21. Fortmann SP, Williams PT, Hulley SB et al. 1981. Effect of health education on dietary behavior: the Stanford Three Community Study. American Journal of Clinical Nutrition 34: 2030-8. (Pubitemid 12198639)
22. Friend K, Levy DT. 2002. Reductions in smoking prevalence and cigarette consumption associated with mass-media campaigns. Health Education Research 17: 85-98. (Pubitemid 34168771)
23. Gaziano TA, Opie LH, Weinstein MC. 2006. Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis. The Lancet 368: 679-86.
24. Gold MR, Siegel JE, Russell LB et al. 1996. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press.
25. Government of Vietnam. 2004. Resolution of the Government No. 204/2004/N-CP dated December 14, 2004 on salary scale of civil servant. Hanoi: Government of Vietnam.
26. Gueyffier F, Boutitie F, Boissel JP et al. 1997. Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men: a meta-analysis of individual patient data from randomized, con-trolled trials. Annals of Internal Medicine 126: 761-7. (Pubitemid 27209641)
27. He FJ, MacGregor GA. 2002. Effect of modest salt reduction on blood pressure: a meta-analysis of randomized trials. Implications for public health. Journal of Human Hypertension 16: 761-70. (Pubitemid 36007929)
28. Hutton G, Baltussen R. 2005. Cost valuation in resource-poor settings. Health Policy and Planning 20: 252-9. (Pubitemid 40942568)
29. Hutubessy R, Chisholm D, Edejer TT. 2003. Generalized cost-effectiveness analysis for national-level priority-setting in the health sector. Cost Effectiveness and Resource Allocation 1: 8.
30. Intersalt Cooperative Research Group. 1988. Intersalt: an international study of electrolyte excretion and blood pressure. Results for 24 hour urinary sodium and potassium excretion. British Medical Journal 297: 319-28.
31. Khai GP, Viet LN, Son TP et al. 2008. Epidemiological survey of hypertension and its risk factors in Vietnam. Presentation at the World Health Organization's office, Hanoi, Vietnam.
32. Kottke TE, Gatewood LC, Wu SC et al. 1988. Preventing heart disease: is treating the high risk sufficient? Journal of Clinical Epidemiology 41: 1083-93. (Pubitemid 19037937)
33. Lauer JA, Rohrich K, Wirth H et al. 2003. PopMod: a longitudinal population model with two interacting disease states. Cost Effectiveness and Resource Allocation 1: 6.
34. Law MR, Frost CD, Wald NJ. 1991. By how much does dietary salt reduction lower blood pressure? III. Analysis of data from trials of salt reduction. British Medical Journal 302: 819-24.
35. Levy DT, Bales S, Lam NT et al. 2006. The role of public policies in reducing smoking and deaths caused by smoking in Vietnam: results from the Vietnam tobacco policy simulation model. Social Science & Medicine 62: 1819-30. (Pubitemid 43243276)
36. Lim SS, Gaziano TA, Gakidou E et al. 2007. Prevention of cardiovascular disease in high-risk individuals in low-income and middle-income countries: health effects and costs. The Lancet 370: 2054-62. (Pubitemid 50007974)
37. MacMahon S, Peto R, Cutler J et al. 1990. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. The Lancet 335: 765-74. (Pubitemid 20106689)
38. MacMahon S, Rodgers A. 1993. The effects of antihypertensive treat-ment on vascular disease: reappraisal of the evidence in (1994). Journal of Vascular Medicine and Biology 4: 265-5.
39. MOH. 2003. Report on results of the Vietnam National Health Survey 2001-2002. Hanoi: Ministry of Health and General Statistics Office of Vietnam.
40. MOH. 2007. Prevention of Hypertension Project for the period 2008-2010. Hanoi: Ministry of Health of Vietnam.
41. MOH. 2008. Joint Annual Health Review 2008: Health Financing in Viet Nam. Hanoi: Ministry of Health of Vietnam.
42. MSH. 2007. International Drug Price Indicator Guide. Boston, MA: Management Sciences for Health.
43. Murray CJ, Evans DB, Acharya A et al. 2000. Development of WHO guidelines on generalized cost-effectiveness analysis. Health Economics 9: 235-51. (Pubitemid 30248640)
44. Murray CJL, Lauer JA, Hutubessy RCW et al. 2003. Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk. The Lancet 361: 717-25. (Pubitemid 36293625)
45. Neal B, MacMahon S, Chapman N. 2000. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. The Lancet 356: 1955-64.
46. Nishtar S. 2002. Prevention of coronary heart disease in south Asia. The Lancet 360: 1015-8. (Pubitemid 35284116)
47. O'Connor PJ. 2003. Overcome clinical inertia to control systolic blood pressure. Archives of Internal Medicine 163: 2677-8. (Pubitemid 37517407)
48. Patrono C, Coller B, FitzGerald GA et al. 2004. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. The American College of Chest Physicians 126: 234-64.
49. Prospective Studies Collaboration. 1995. Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. The Lancet 346: 1647-53.
50. Puska P, Salonen JT, Nissinen A et al. 1983. Change in risk factors for coronary heart disease during 10 years of a community interven-tion programme (North Karelia project). British Medical Journal (Clinical Research Edition) 287: 1840-4. (Pubitemid 14205221)
51. Rose G, Khaw KT, Marmot M. 2008. Rose's Strategy of Preventive Medicine: The Complete Original Text. New York: Oxford University Press.
52. Rubinstein A, Mart́ SG, Souto A et al. 2009. Generalized cost-effectiveness analysis of a package of interventions to reduce cardiovascular disease in Buenos Aires, Argentina. Cost Effectiveness and Resource Allocation 7: 10.
53. Stein EA, Lazkarzewski P, Steiner P. 1993. Lovastatin 5-year safety and efficacy study. Archives of Internal Medicine 153: 1079-87.
54. Tian HG, Guo ZY, Hu G et al. 1995. Changes in sodium intake and blood pressure in a community-based intervention project in China. Journa of Human Hyprnsion 9 959-68 (Pubitemid 26008388)
55. Tikkanen MJ, Helve E, Jäättelä A et al. 1988. Comparison between lovastatin and gemfibrozil in the treatment of primary hyperchol-esterolemia: the Finnish Multicenter Study. The American Journal of Cardiology 62: 35J-43J. (Pubitemid 18263854)
56. Tsugane S. 2005. Salt, salted food intake, and risk of gastric cancer: epidemiologic evidence. Cancer Science 96: 1-6. (Pubitemid 40310017)
57. Tsugane S, Sasazuki S, Kobayashi M et al. 2004. Salt and salted food intake and subsequent risk of gastric cancer among middle-aged Japanese men and women. British Journal of Cancer 90: 128-34. (Pubitemid 38174951)
58. Tuan NT, Tuong PD, Popkin BM. 2008. Body mass index (BMI) dynamics in Vietnam. European Journal of Clinical Nutrition 62: 78-86
59. UN-EU. 2007. UN-EU Guidelines for Financing of Local Costs in Development Co-operation with Vietnam. UN Agencies, the Embassies of the EU Member States, and the EC Delegation to Vietnam.
60. WHO. 2001. Macroeconomics and Health: Investing in Health for Economic Development. Geneva: World Health Organization.
61. WHO. 2002. The World Health Report 2002: Reducing Risks, Promoting Healthy Life. Geneva: World Health Organization.
62. WHO. 2007. Reducing Salt Intake in Populations: Report of a WHO Forum and Technical Meeting. Geneva: World Health Organization.
63. Williams B. 2006. Evolution of hypertensive disease: a revolution in guidelines. The Lancet 368: 6-8. (Pubitemid 43947185)